Condition
Stage III Breast Cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4)
Total Trials
1
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
1 treatments under study, led by Wholebody Fdg Petct Alone
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
Not Applicable (1)
Trial Status
Completed1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (1)
Research Network
Common Treatments
- Wholebody Fdg Petct Alone1
Active Sponsors
- Cancer Care Ontario1
- Ontario Clinical Oncology Group (OCOG)1
Top Investigators
Ontario Clinical Oncology Group (OCOG)
Juravinski Hospital and Cancer Centre
Princess Margaret Hospital, Canada
Sunnybrook Health Sciences Centre
St. Michael's Hospital, CIBC Breast Centre
Related Conditions
- Stage Iib Breast Cancer T3n01